Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
| Dividenden-Strategie | 8 / 15 |
| HGI-Strategie | 9 / 18 |
| Levermann-Strategie | -5 / 13 |
News
New S32K5 microcontroller family advances zonal SDV architectures and extends the NXP CoreRide platform
NUREMBERG, Germany, March 11, 2025 (GLOBE NEWSWIRE) -- EMBEDDED WORLD -- NXP Semiconductors N.V. (NASDAQ: NXPI), the trusted partner for innovative solutions in the automotive market, today unveiled its new S32K5 family of automotive microcontrollers (MCU), the automotive industry's first 16nm FinFET MCU with embedded magnetic RAM (MRAM) . The S32K5 MCU family will extend the NXP CoreRide platform with pre-integrated zonal and electrification system solutions for scalable software-defined vehicle (SDV) architectures.» Mehr auf globenewswire.com
NXP Semiconductors Announces Quarterly Dividend
EINDHOVEN, The Netherlands, March 06, 2025 (GLOBE NEWSWIRE) -- As part of its ongoing capital return program, NXP Semiconductors N.V. (NASDAQ: NXPI) today announced that its board of directors has approved the payment of an interim dividend. The actions are based on the continued and significant strength of the NXP capital structure, and the board's confidence in the company's ability to drive long-term growth and strong cash flow.» Mehr auf globenewswire.com
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.» Mehr auf businesswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
| (EUR) | Sep. 2024 | |
|---|---|---|
| Umsatz | 14,35 Mio | - |
| Bruttoeinkommen | 14,35 Mio | - |
| Nettoeinkommen | 18,00 Mio | - |
| EBITDA | 0,00 | - |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 625,70 Mio€ |
Anzahl Aktien | 46,82 Mio |
52 Wochen-Hoch/Tief | 14,13€ - 12,78€ |
Dividendenrendite | 4,28% |
Dividenden TTM | 0,57€ |
Nächste Dividende | 0,0481€ |
Beta | 0,32 |
KGV (PE Ratio) | 9,47 |
KGWV (PEG Ratio) | 0,07 |
KBV (PB Ratio) | 0,98 |
KUV (PS Ratio) | 21,54 |
Unternehmensprofil
Nuveen Select Tax-Free Income Portfolio ist ein geschlossener, festverzinslicher Investmentfonds, der von Nuveen Investments Inc. aufgelegt wurde. Der Fonds wird gemeinsam von Nuveen Fund Advisors LLC und Nuveen Asset Management, LLC verwaltet. Er investiert in die festverzinslichen Märkte der Vereinigten Staaten. Der Fonds investiert in kommunale Wertpapiere mit Investment-Grade-Rating (Baa und BBB oder besser). Die Performance des Portfolios wird mit dem Standard & Poor's (S&P) National Municipal Bond Index und dem Lipper General and Insured Unleveraged Municipal Debt Funds Average verglichen. Der Nuveen Select Tax-Free Income Portfolio wurde am 19. März 1992 aufgelegt und hat seinen Sitz in den Vereinigten Staaten.
| Name | NUVEEN SEL. TAX-FREE INC. |
| CEO | Thomas C. Spalding Jr., C.F.A. |
| Sitz | Chicago, il USA |
| Website | |
| Börsengang | |
| Mitarbeiter | 0 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NYSE | NXP |
Assets entdecken
Shareholder von NUVEEN SEL. TAX-FREE INC. investieren auch in folgende Assets
